Request To Download Free Sample of This Strategic Report@ COPD and asthma devices are crucial in the management and treatment of respiratory diseases, providing relief and improving the quality of ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

AstraZeneca's three-drug inhaler Breztri Aerosphere has shown efficacy for uncontrolled asthma in a pair of phase 3 trials ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Asthma, a chronic respiratory disease affecting over 262 million people globally, poses a significant public health challenge ...

Given the rising prevalence of cognitive impairment in COPD, researchers have called for increased efforts to identify risk factors and intervene earlier.

The replicate confirmatory KALOS and LOGOS trials evaluated BGF in participants with severe asthma inadequately controlled with standard of care.

Adult incident asthma is associated with a lower number of daily steps, suggesting that exercise may modify asthma risk.